secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001140361-24-035233
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q2 revenue $225M (+20% YoY); operating loss narrows to $66M; key pipeline milestones
--------------------------------------------------------------------------------

- Total revenue $225M (up 20% YoY); loss from operations $66M vs $91M loss in Q2 2023; non-GAAP loss from ops $35M.
- WAINUA Q2 royalty revenue $4M; approved in Canada; U.S. launch progressing with AstraZeneca.
- Olezarsen NDA for FCS accepted for Priority Review, PDUFA Dec 19, 2024; Phase 3 sHTG studies fully enrolled, data H2:2025.
- Donidalorsen Phase 3 OASIS data published in NEJM; preparing U.S. NDA and EU MAA for HAE.
- Cash and short-term investments $2.1B; reaffirmed 2024 guidance; projects year-end cash $1.7B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036124035233/0001140361-24-035233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036124035233/ef20033414_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-035233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer